Abstract
This prospective observational study aimed to assess the diagnostic utility of point‐of‐care (POC) high‐sensitivity troponin (hs‐cTn) within an ED chest pain pathway. Patients had paired laboratory hs‐cTnT and POC hs‐cTnI on arrival. Clinical care utilised the hs‐cTnT result. Allocation to risk classes was compared between hs‐cTnT and POC hs‐cTnI. AMI was adjudicated blinded to the POC result. Of 184 patients, 14 (7.6%) had AMI. Twenty‐one (11.4%) had AMI ruled out by hs‐cTnT and 59 (32.1%) by POC, both with 100% sensitivity. The POC test returned invalid results in 17 patients (8.5%). A POC hs‐cTnI assay within a clinical pathway may effectively risk stratify for AMI.
Funding Information
  • Canterbury Medical Research Foundation
  • Siemens Healthineers
  • Health Research Council of New Zealand (19/234)